FibroGen (FGEN) Competitors $11.84 -0.19 (-1.58%) Closing price 04:00 PM EasternExtended Trading$12.00 +0.16 (+1.35%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. TLSA, EPRX, CCCC, CGTX, ENTA, IPHA, NLTX, SXTC, AARD, and DERMShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Tiziana Life Sciences (TLSA), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), Cognition Therapeutics (CGTX), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), China SXT Pharmaceuticals (SXTC), Aardvark Therapeutics (AARD), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Tiziana Life Sciences Eupraxia Pharmaceuticals C4 Therapeutics Cognition Therapeutics Enanta Pharmaceuticals Innate Pharma Neoleukin Therapeutics China SXT Pharmaceuticals Aardvark Therapeutics Journey Medical Tiziana Life Sciences (NASDAQ:TLSA) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do analysts prefer TLSA or FGEN? FibroGen has a consensus price target of $43.00, indicating a potential upside of 263.18%. Given FibroGen's stronger consensus rating and higher possible upside, analysts plainly believe FibroGen is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings and valuation, TLSA or FGEN? Tiziana Life Sciences has higher earnings, but lower revenue than FibroGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/AFibroGen$29.62M1.61-$47.58M-$0.38-31.16 Is TLSA or FGEN more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A FibroGen -3.86%N/A -27.34% Do insiders and institutionals have more ownership in TLSA or FGEN? 72.7% of FibroGen shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 2.0% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to TLSA or FGEN? In the previous week, Tiziana Life Sciences had 5 more articles in the media than FibroGen. MarketBeat recorded 9 mentions for Tiziana Life Sciences and 4 mentions for FibroGen. Tiziana Life Sciences' average media sentiment score of 0.18 beat FibroGen's score of 0.11 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TLSA or FGEN? Tiziana Life Sciences has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. SummaryTiziana Life Sciences and FibroGen tied by winning 6 of the 12 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.65M$2.56B$5.78B$10.19BDividend YieldN/A57.24%5.73%4.61%P/E Ratio-31.1623.2874.8626.40Price / Sales1.61688.63540.53124.73Price / CashN/A27.5625.8129.91Price / Book-0.235.4013.256.28Net Income-$47.58M$32.95M$3.29B$270.38M7 Day Performance6.09%0.21%0.47%2.70%1 Month Performance24.76%4.10%4.60%5.99%1 Year Performance0.77%-2.91%73.42%25.94% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.465 of 5 stars$11.84-1.6%$43.00+263.2%+2.4%$48.65M$29.62M-31.16570News CoverageAnalyst UpgradeGap DownTLSATiziana Life Sciences0.551 of 5 stars$1.62-2.4%N/A+82.7%$193.97MN/A0.008News CoverageShort Interest ↑Gap UpEPRXEupraxia Pharmaceuticals2.4916 of 5 stars$5.27-2.2%$11.00+108.7%+106.6%$193.82MN/A0.0029CCCCC4 Therapeutics3.2551 of 5 stars$2.71-0.4%$8.00+195.2%-58.7%$193.59M$35.58M-1.72150News CoveragePositive NewsAnalyst UpgradeGap UpCGTXCognition Therapeutics2.6593 of 5 stars$2.40-8.0%$2.83+18.1%+261.6%$191.90MN/A0.0020Short Interest ↑Gap UpENTAEnanta Pharmaceuticals4.1873 of 5 stars$8.91+0.7%$22.25+149.7%-33.4%$189.20M$67.64M-2.06160News CoverageAnalyst ForecastIPHAInnate Pharma2.8109 of 5 stars$2.04-0.5%$11.00+439.2%-11.5%$188.97M$21.77M0.00220News CoveragePositive NewsUpcoming EarningsNLTXNeoleukin TherapeuticsN/A$19.95+1.7%N/A-54.7%$187.49MN/A-6.4190High Trading VolumeSXTCChina SXT Pharmaceuticals1.2992 of 5 stars$1.65+2.5%N/A-62.8%$186.80M$1.74M0.0090News CoveragePositive NewsShort Interest ↓Gap DownHigh Trading VolumeAARDAardvark Therapeutics3.6793 of 5 stars$8.20-4.7%$32.60+297.6%N/A$186.59MN/A0.0018Positive NewsGap UpDERMJourney Medical2.446 of 5 stars$7.01flat$12.17+73.6%+37.8%$184.43M$56.13M0.0090 Related Companies and Tools Related Companies Tiziana Life Sciences Competitors Eupraxia Pharmaceuticals Competitors C4 Therapeutics Competitors Cognition Therapeutics Competitors Enanta Pharmaceuticals Competitors Innate Pharma Competitors Neoleukin Therapeutics Competitors China SXT Pharmaceuticals Competitors Aardvark Therapeutics Competitors Journey Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts